RT Journal Article
SR Electronic
T1 Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy
JF British Journal of Ophthalmology
JO Br J Ophthalmol
FD BMJ Publishing Group Ltd.
SP 10
OP 13
DO 10.1136/bjophthalmol-2011-300183
VO 96
IS 1
A1 Nathan C Steinle
A1 Naina Gupta
A1 Alex Yuan
A1 Rishi P Singh
YR 2012
UL http://bjo.bmj.com/content/96/1/10.abstract
AB Chronic central serous retinopathy (CSR) is characterised by frequent exacerbations and a poor visual prognosis. Very few therapies exist for chronic CSR, and the existing therapies are often ineffective. Thus, novel therapies to combat this frustrating disorder are needed. Presented here is a case detailing a patient with chronic CSR with persistent subfoveal fluid of 2 years' duration that completely resolved with 1 month of oral rifampin therapy. As a cytochrome P450, 3A4 inducer, rifampin is thought to favourably alter the metabolism of endogenous steroids, thereby leading to an improvement in CSR manifestations.